- Home
- DM vs APLT Comparison
DM vs APLT Comparison
Compare DM & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DM
- APLT
- Stock Information
- Founded
- DM 2015
- APLT 2016
- Country
- DM United States
- APLT United States
- Employees
- DM N/A
- APLT N/A
- Industry
- DM Industrial Machinery/Components
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- DM Technology
- APLT Health Care
- Exchange
- DM Nasdaq
- APLT Nasdaq
- Market Cap
- DM 138.7M
- APLT 128.0M
- IPO Year
- DM N/A
- APLT 2019
- Fundamental
- Price
- DM $2.86
- APLT $0.88
- Analyst Decision
- DM Hold
- APLT Buy
- Analyst Count
- DM 1
- APLT 6
- Target Price
- DM $5.50
- APLT $6.10
- AVG Volume (30 Days)
- DM 250.1K
- APLT 12.1M
- Earning Date
- DM 10-31-2024
- APLT 11-07-2024
- Dividend Yield
- DM N/A
- APLT N/A
- EPS Growth
- DM N/A
- APLT N/A
- EPS
- DM N/A
- APLT N/A
- Revenue
- DM $168,283,000.00
- APLT N/A
- Revenue This Year
- DM N/A
- APLT N/A
- Revenue Next Year
- DM $6.25
- APLT $2,664.24
- P/E Ratio
- DM N/A
- APLT N/A
- Revenue Growth
- DM N/A
- APLT N/A
- 52 Week Low
- DM $2.81
- APLT $0.84
- 52 Week High
- DM $11.80
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- DM 17.45
- APLT 16.80
- Support Level
- DM $3.24
- APLT $0.95
- Resistance Level
- DM $4.17
- APLT $1.14
- Average True Range (ATR)
- DM 0.19
- APLT 0.16
- MACD
- DM -0.09
- APLT 0.05
- Stochastic Oscillator
- DM 3.66
- APLT 4.60
About DM Desktop Metal Inc.
Desktop Metal Inc manufactures 3D printing to make metal and carbon fiber 3D printing accessible to all engineers, designers, and manufacturers. 3D metal printing helps in the design and development of automotive parts, consumer goods, manufacture of industrial equipment, and design of mechanical systems. The company ships its product to markets in the Americas, Europe Middle East and Africa (EMEA), and Asia Pacific (APAC). It derives maximum revenue from Americas.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.